Systemic inflammation and oxidative stress contribute to acute kidney injury after transcatheter aortic valve implantation.
acute kidney injury
severe aortic stenosis
systemic inflammation
transcatheter aortic valve implantation
Journal
Cardiology journal
ISSN: 1898-018X
Titre abrégé: Cardiol J
Pays: Poland
ID NLM: 101392712
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
09
2019
accepted:
11
05
2020
revised:
24
04
2020
pubmed:
22
12
2020
medline:
7
10
2022
entrez:
21
12
2020
Statut:
ppublish
Résumé
Acute kidney injury (AKI) is a frequent complication of transcatheter aortic valve implantation (TAVI) and has been linked to preexisting comorbidities, peri-procedural hypotension, and systemic inflammation. The extent of systemic inflammation after TAVI is not fully understood. Our aim was to characterize the inflammatory response after TAVI and evaluate its contribution to the mechanism of post-procedural AKI. One hundred and five consecutive patients undergoing TAVI at our institution were included. We analyzed the peri-procedural inflammatory and oxidative stress responses by measuring a range of biomarkers (including C-reactive protein [hsCRP], cytokine levels, and myeloperoxidase [MPO]), before TAVI and 6, 24, and 48 hours post-procedure. We correlated this with changes in renal function and patient and procedural characteristics. We observed a significant increase in plasma levels of pro-inflammatory cytokines (hsCRP, interleukin 6, tumor necrosis factor alpha receptors) and markers of oxidative stress (MPO) after TAVI. The inflammatory response was significantly greater after transapical (TA) TAVI compared to transfemoral (TF). This was associated with a higher incidence of AKI in the TA cohort compared to TF (44% vs. 8%, respectively, p < 0.0001). The incidence of AKI was significantly lower when N-acetylcysteine (NAC) was given peri-procedurally (12% vs. 38%, p < 0.005). In multivariate analysis, only the TA approach and no use of NAC before the procedure were independent predictors of AKI. TAVI creates a significant post-procedural inflammatory response, more so with the TA approach. Mechanisms of AKI after TAVI are complex. Inflammatory response, hypoperfusion, and oxidative stress may all play a part and are potential therapeutic targets to reduce/prevent AKI.
Sections du résumé
BACKGROUND
Acute kidney injury (AKI) is a frequent complication of transcatheter aortic valve implantation (TAVI) and has been linked to preexisting comorbidities, peri-procedural hypotension, and systemic inflammation. The extent of systemic inflammation after TAVI is not fully understood. Our aim was to characterize the inflammatory response after TAVI and evaluate its contribution to the mechanism of post-procedural AKI.
METHODS
One hundred and five consecutive patients undergoing TAVI at our institution were included. We analyzed the peri-procedural inflammatory and oxidative stress responses by measuring a range of biomarkers (including C-reactive protein [hsCRP], cytokine levels, and myeloperoxidase [MPO]), before TAVI and 6, 24, and 48 hours post-procedure. We correlated this with changes in renal function and patient and procedural characteristics.
RESULTS
We observed a significant increase in plasma levels of pro-inflammatory cytokines (hsCRP, interleukin 6, tumor necrosis factor alpha receptors) and markers of oxidative stress (MPO) after TAVI. The inflammatory response was significantly greater after transapical (TA) TAVI compared to transfemoral (TF). This was associated with a higher incidence of AKI in the TA cohort compared to TF (44% vs. 8%, respectively, p < 0.0001). The incidence of AKI was significantly lower when N-acetylcysteine (NAC) was given peri-procedurally (12% vs. 38%, p < 0.005). In multivariate analysis, only the TA approach and no use of NAC before the procedure were independent predictors of AKI.
CONCLUSIONS
TAVI creates a significant post-procedural inflammatory response, more so with the TA approach. Mechanisms of AKI after TAVI are complex. Inflammatory response, hypoperfusion, and oxidative stress may all play a part and are potential therapeutic targets to reduce/prevent AKI.
Identifiants
pubmed: 33346373
pii: VM/OJS/J/65640
doi: 10.5603/CJ.a2020.0169
pmc: PMC9550344
doi:
Substances chimiques
Biomarkers
0
Interleukin-6
0
Tumor Necrosis Factor-alpha
0
C-Reactive Protein
9007-41-4
Peroxidase
EC 1.11.1.7
Acetylcysteine
WYQ7N0BPYC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
824-835Références
Circulation. 2003 Feb 11;107(5):721-6
pubmed: 12578875
J Am Coll Cardiol. 2013 Sep 3;62(10):869-77
pubmed: 23707321
Am J Kidney Dis. 2004 Sep;44(3):420-8
pubmed: 15332214
Eur Heart J. 2012 Oct;33(19):2403-18
pubmed: 23026477
Heart. 2012 Nov;98(22):1641-6
pubmed: 22914532
Heart Fail Rev. 2011 Nov;16(6):553-67
pubmed: 21400231
Heart. 2012 Nov;98(21):1541-2
pubmed: 22976201
Nephrology (Carlton). 2012 Jul;17(5):445-51
pubmed: 22390156
N Engl J Med. 2000 Jul 20;343(3):180-4
pubmed: 10900277
Ren Fail. 2013 Oct;35(9):1216-22
pubmed: 23924312
Catheter Cardiovasc Interv. 2011 May 1;77(6):881-9
pubmed: 21061244
J Am Soc Nephrol. 2011 Nov;22(11):2057-67
pubmed: 21949094
Cytokine. 2009 Feb;45(2):92-8
pubmed: 19128984
J Invasive Cardiol. 2012 Aug;24(8):407-11
pubmed: 22865312
Circ Cardiovasc Interv. 2012 Jun;5(3):415-23
pubmed: 22668556
Circulation. 2008 Apr 15;117(15):1936-44
pubmed: 18378613
J Am Heart Assoc. 2016 Feb 19;5(2):
pubmed: 26896474
Biomark Med. 2010 Apr;4(2):265-80
pubmed: 20406069
J Am Coll Cardiol. 2010 Jan 19;55(3):243-50
pubmed: 20117403
Circulation. 2012 Mar 20;125(11):1347-55
pubmed: 22322531
Free Radic Biol Med. 1989;6(6):593-7
pubmed: 2546864
N Engl J Med. 2012 May 3;366(18):1686-95
pubmed: 22443479
Am Heart J. 2011 Apr;161(4):735-9
pubmed: 21473973
Crit Care. 2007;11(2):R31
pubmed: 17331245
Nephrol Dial Transplant. 2006 May;21(5):1240-7
pubmed: 16390850
J Am Coll Cardiol. 2013 Apr 16;61(15):1585-95
pubmed: 23500308
J Am Soc Nephrol. 2004 Feb;15(2):251-60
pubmed: 14747371
Cytokine. 2004 Jul 21-Aug 7;27(2-3):81-9
pubmed: 15242697
J Am Coll Cardiol. 2013 Sep 3;62(10):878-80
pubmed: 23707322
J Am Soc Nephrol. 2011 Sep;22(9):1748-57
pubmed: 21836143
Eur J Cardiothorac Surg. 2011 Jun;39(6):835-42; discussion 842-3
pubmed: 21186126
Am J Kidney Dis. 2003 Mar;41(3):571-9
pubmed: 12612980
J Am Coll Cardiol. 2012 Mar 27;59(13):1134-41
pubmed: 22440213
Eur Heart J. 2012 Oct;33(19):2399-402
pubmed: 22851655
Heart. 2014 Dec;100(24):1939-45
pubmed: 25053724
Am J Kidney Dis. 2005 Oct;46(4):610-20
pubmed: 16183415
Eur Heart J. 2012 Jun;33(12):1459-68
pubmed: 22285582